US Stock Market News | Tempus AI debuts on the US capital market, opening up more than 12%
On Friday, Tempus AI, supported by SoftBank and providing data and analysis tools for precision medicine, debuted on the US capital market, opening up more than 12% and reaching a high of $43.02. The IPO price was $37. Tempus AI's core revenue comes from its genetic testing services, which target healthcare providers, life science companies, researchers, and professionals focused on cancer diagnostics. The services provided by the company include next-generation sequencing (NGS) diagnostics, molecular genotyping, and other advanced tests. In addition, Tempus AI generates revenue by providing clinical, molecular, and imaging databases to pharmaceutical and biotechnology companies, along with a range of analysis and computational tools. As of March 31, 2024, Tempus AI's 12-month revenue was $5.62 billion
According to Zhitong Finance APP, on Friday, Tempus AI (TEM.US), supported by SoftBank and providing data and analysis tools for precision medicine, made its debut on the US capital market, opening more than 12% higher with a peak of $43.02. The IPO price was $37.
The core revenue source of Tempus AI is its genomic testing services, targeting healthcare providers, life science companies, researchers, and professionals focused on cancer diagnostics. The services provided by the company include next-generation sequencing (NGS) diagnostics, molecular genotyping, and other advanced tests. In addition, Tempus AI generates revenue by providing clinical, molecular, and imaging databases to pharmaceutical and biotechnology companies, along with a range of analysis and computational tools. As of March 31, 2024, Tempus AI's 12-month revenue was $5.62 billion